The committee will discuss new drug application (NDA) 213805, for the hypoxia inducible factor prolyl hydroxylase inhibitor, roxadustat tablets, submitted by FibroGen, Inc., for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis and on dialysis.
Back to All Events
Earlier Event: June 24
Oncologic Drugs Advisory Committee
Later Event: September 2
Cellular, Tissue, and Gene Therapies Advisory Committee